By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting out of Tel Aviv, Israel, by NewsRx editors, research stated, "Lung cancer is the most frequent and one of the most deadly cancer types and is classified into small cell lung cancer and non-small cell lung cancer (NSCLC). Transforming growth factor beta (TGF beta) regulates a wide array of cell functions and plays a major role in lung diseases, including NSCLC."
Our news journalists obtained a quote from the research from Tel Aviv University, "TGF beta signals through the complex of TGF beta type I and type II receptors, triggering Smad and non-Smad signaling pathways such as PI3K/Akt and MEK1/ERK. We investigated the role of TGF beta 1 on the progression of the murine lung adenocarcinoma cell line LP07. Furthermore, we undertook a retrospective study with tissue samples from stage I and II NSCLC patients to assess the clinical pathologic role and prognostic significance of T beta RI expression. We demonstrated that although lung cancer cell monolayers responded to TGF beta 1 anti-mitogenic effects and TGF beta 1 pulse (24 h treatment) delayed tumor growth at primary site; a switch towards malignant progression upon TGF beta 1 treatment was observed at the metastatic site. In our model, TGF beta 1 modulated in vitro clonogenicity, protected against stress-induced apoptosis and increased adhesion, spreading, lung retention and metastatic outgrowth. PI3K and MEK1 signaling pathways were involved in TGF beta 1-mediated metastasis stimulation. Several of these TGF beta responses were also observed in human NSCLC cell lines. In addition, we found that a higher expression of T beta RI in human lung tumors is associated with poor patient's overall survival by univariate analysis, while multivariate analysis did not reach statistical significance."
According to the news editors, the research concluded: "Although additional detailed analysis of the endogenous signaling in vivo and in vitro is needed, these studies may provide novel molecular targets for the treatment of lung cancer."
For more information on this research see: TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clinical & Experimental Metastasis, 2013;30(8):993-1007. Clinical & Experimental Metastasis can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting P.F. Vazquez, Tel Aviv University, George S Wise Fac Life Sci, Dept. of Neurobiochem, IL-69978 Tel Aviv, Israel. Additional authors for this research include M.J. Carlini, M.C. Daroqui, L. Colombo, M.L. Dalurzo, D.E. Smith, J. Grasselli, M.G. Pallotta, M. Ehrlich, E. Joffe and L. Puricelli.
Keywords for this news article include: Asia, Biotechnology, Israel, Tel Aviv, Oncology, Treatment, Lung Neoplasms, Adenocarcinomas, Cancer Gene Therapy, Non-Small Cell Lung Cancer
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC